Biogen Idec appoints new head of R&D

pharmafile | January 6, 2011 | Appointment | Research and Development, Sales and Marketing Biogen IDEC, Douglas Williams, Steven Holtzman, appointment, research and development, sales and marketing 

Biogen Idec has a new head of research and development, appointing Douglas Williams to oversee its global operations.

The position includes responsibility for the US biotech’s discovery research, development, clinical and regulatory affairs operations.

Douglas most recently served at ZymoGenetics as chief executive and has previously been head of research at Immunex.

Advertisement

Biogen Idec has also appointed Steven Holtzman as executive VP of corporate development.

He will oversee corporate strategy, business development, portfolio management, program leadership and Biogen’s New Ventures fund.

Steven most recently as chairman and chief executive of Infinity Pharmaceuticals, which he also founded. Prior to this he served as chief business officer of Millennium Pharmaceuticals.

Both Steven and Douglas will report to Biogen Idec Chief Executive Officer George Scangos.

Meanwhile, Biogen said Michael Lytton, who has been leading its business development efforts, will be leaving following the completion of “select, ongoing projects”.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content